drugset / Trial / NCT00135330
An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus
RandomizedParallel-groupOpen-labelTreatment
Summary
This protocol is designed to evaluate the metabolic effects of adding exenatide, rosiglitazone, or both to an existing regimen of metformin in subjects with inadequate glycemic control.
Timeline
- Start
- 2005-10
- Primary completion
- 2008-07
- Completion
- 2008-07
Publications
- Fineman MS, Mace KF, Diamant M, Darsow T, Cirincione BB, Booker Porter TK, Kinninger LA, Trautmann ME. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab. 2012 Jun;14(6):546-54. doi: 10.1111/j.1463-1326.2012.01561.x. Epub 2012 Feb 10.
- DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC. Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care. 2010 May;33(5):951-7. doi: 10.2337/dc09-1521. Epub 2010 Jan 27.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exenatide | Peptide | 5 ug | Subcutaneous |
| Subject | Exenatide | Peptide | 10 ug | Subcutaneous |
| Subject | Rosiglitazone | Small molecule | 2 mg | Oral |
| Subject | Rosiglitazone | Small molecule | 4 mg | Oral |